Novartis Deal With Vertex, NYSE Listing Bolster U.S. Presence
Executive Summary
Novartis has augmented its U.S. research profile with a long-term drug discovery deal with Cambridge, Mass.-based Vertex Pharmaceuticals.
You may also be interested in...
Merck Adds To Cancer Research Aura With Vertex Aurora Kinase Inhibitors
Merck and Vertex expect to begin clinical trials of the aurora kinase inhibitor anticancer agent VX-680 during the second half of the year
Merck Adds To Cancer Research Aura With Vertex Aurora Kinase Inhibitors
Merck and Vertex expect to begin clinical trials of the aurora kinase inhibitor anticancer agent VX-680 during the second half of the year
Novartis Rx Exec Changes Include U.S. COO Epstein To Oncology Unit Head
Novartis Pharmaceutical U.S. Chief Operating Officer David Epstein will head the Swiss company's new global oncology business unit effective Sept. 1.